Targeting the ubiquitin-mediated proteasome degradation of p53 for cancer therapy

Area of Science:

• Oncology
• Molecular Biology
• Drug Discovery

Background:

• Targeted cancer therapies like kinase inhibitors have advanced treatment but lack broad efficacy.
• The p53 tumor suppressor pathway is frequently inactivated in human cancers, even when wild-type p53 is present.
• Restoring p53 pathway function is a key goal for developing more effective cancer treatments.

Purpose of the Study:

• To review progress in developing therapies that reactivate the p53 tumor suppressor pathway.
• To highlight the development of inhibitors targeting MDM2 (mouse double minute 2 homolog) and deubiquitinating enzymes (DUBs).
• To discuss the potential of targeting upstream components of the p53 ubiquitination pathway.

Main Methods:

• Review of current research on p53 pathway reactivation strategies.
• Focus on inhibitors of p53-MDM2 and p53-MDMX interactions.
• Analysis of MDM2 E3 ligase inhibitors and deubiquitinating enzyme (DUB) inhibitors.

Main Results:

• Significant progress has been made in developing compounds that interfere with p53 regulation by MDM2 and MDMX.
• Inhibitors targeting MDM2 and specific DUBs are emerging as promising therapeutic strategies.
• Targeting upstream elements of the p53 ubiquitination pathway presents a viable therapeutic option.

Conclusions:

• Reactivating the p53 pathway holds significant therapeutic potential for a broad range of cancers.
• MDM2 and DUB inhibitors represent key advancements in p53-targeted cancer therapy.
• Further development of upstream pathway inhibitors could offer additional treatment avenues.